Education Archive

Sustained efficacy of Cervarix 6.4 years following vaccination

Six-year follow-up results reported in The Lancet show that the bivalent HPV vaccine Cervarix shows sustained efficacy when targeted at young girls before they become sexually active. Vaccine efficacy against incident infection with HPV-16/18 was 95%, and against 12-month persistent infection was 100%. Vaccine efficacy against CIN2+ was 100% for lesions associated with HPV-16/18, and 72% for lesions independent of HPV type.